TY - JOUR
T1 - Hypertension and hemodialysis
T2 - Pathophysiology and outcomes in adult and pediatric populations
AU - Van Buren, Peter N.
AU - Inrig, Jula K.
N1 - Funding Information:
Dr. PVB is supported by NIH grant F32 DK085965-O1A1. Dr. JKI is supported by NIH grant K23 HLO92297. She has also received investigator-initiated research support from Genzyme.
PY - 2012/3
Y1 - 2012/3
N2 - Hypertension is prevalent in adult and pediatric end-stage renal disease patients on hemodialysis. Volume overload is a primary factor contributing to hypertension, and attaining true dry weight remains a priority for nephrologists. Other contributing factors to hypertension include activation of the sympathetic and renin-angiotensin- aldosterone systems, endothelial cell dysfunction, arterial stiffness, exposure to hypertensinogenic drugs, and electrolyte imbalances during hemodialysis. Epidemiologic studies in adults show that uncontrolled hypertension results in cardiovascular morbidity, but reveal increased mortality risk at low blood pressure, so that it remains unclear what the target blood pressure should be. Despite the lack of a definitive BP target, gradual dry weight reduction should be the first intervention for BP control. Renin-angiotensin-aldosterone system inhibitors have been shown to improve cardiovascular morbidity and mortality and are recommended as the initial pharmacologic therapy for hypertensive hemodialysis patients. Short-daily or nocturnal hemodialysis are also good therapeutic options for these patients. It is already established that hypertension in pediatric hemodialysis patients is associated with adverse cardiovascular outcomes, and there is emerging evidence that the mechanisms causing hypertension are similar to adults. Hypertension in adult and pediatric hemodialysis patients warrants aggressive management, although clinical trial evidence of a target BP that improves mortality does not currently exist.
AB - Hypertension is prevalent in adult and pediatric end-stage renal disease patients on hemodialysis. Volume overload is a primary factor contributing to hypertension, and attaining true dry weight remains a priority for nephrologists. Other contributing factors to hypertension include activation of the sympathetic and renin-angiotensin- aldosterone systems, endothelial cell dysfunction, arterial stiffness, exposure to hypertensinogenic drugs, and electrolyte imbalances during hemodialysis. Epidemiologic studies in adults show that uncontrolled hypertension results in cardiovascular morbidity, but reveal increased mortality risk at low blood pressure, so that it remains unclear what the target blood pressure should be. Despite the lack of a definitive BP target, gradual dry weight reduction should be the first intervention for BP control. Renin-angiotensin-aldosterone system inhibitors have been shown to improve cardiovascular morbidity and mortality and are recommended as the initial pharmacologic therapy for hypertensive hemodialysis patients. Short-daily or nocturnal hemodialysis are also good therapeutic options for these patients. It is already established that hypertension in pediatric hemodialysis patients is associated with adverse cardiovascular outcomes, and there is emerging evidence that the mechanisms causing hypertension are similar to adults. Hypertension in adult and pediatric hemodialysis patients warrants aggressive management, although clinical trial evidence of a target BP that improves mortality does not currently exist.
KW - Cardiovascular outcomes
KW - Hemodialysis
KW - Hypertension
KW - Pediatrics
KW - Renin-angiotensin-aldosterone system
UR - http://www.scopus.com/inward/record.url?scp=84857049831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857049831&partnerID=8YFLogxK
U2 - 10.1007/s00467-011-1775-3
DO - 10.1007/s00467-011-1775-3
M3 - Review article
C2 - 21286758
AN - SCOPUS:84857049831
SN - 0931-041X
VL - 27
SP - 339
EP - 350
JO - Pediatric Nephrology
JF - Pediatric Nephrology
IS - 3
ER -